First in human dose calculation of a single-chain bispecific antibody targeting glioma using the MABEL approach.
Teilo H SchallerDavid J SnyderIvan SpasojevicPatrick C GedeonLuis Sanchez-PerezJohn H SampsonPublished in: Journal for immunotherapy of cancer (2021)
The comparison of our MABEL-based starting dose to our in vivo efficacious dose and the theoretical human receptor occupancy strongly supports that our human starting dose of 57.4 ng hEGFRvIII:CD3 bi-scFv/patient kg will be safe.